![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DPCD |
Gene summary for DPCD |
![]() |
Gene information | Species | Human | Gene symbol | DPCD | Gene ID | 25911 |
Gene name | deleted in primary ciliary dyskinesia homolog (mouse) | |
Gene Alias | DPCD | |
Cytomap | 10q24.32 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q5JQQ4 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
25911 | DPCD | cirrhotic2 | Human | Liver | Cirrhotic | 3.00e-09 | 1.10e-01 | 0.0201 |
25911 | DPCD | cirrhotic3 | Human | Liver | Cirrhotic | 1.08e-07 | 1.20e-01 | 0.0215 |
25911 | DPCD | S015 | Human | Liver | HCC | 4.95e-07 | 6.24e-01 | 0.2375 |
25911 | DPCD | S016 | Human | Liver | HCC | 9.09e-05 | 3.40e-01 | 0.2243 |
25911 | DPCD | S027 | Human | Liver | HCC | 3.58e-02 | 4.96e-01 | 0.2446 |
25911 | DPCD | S028 | Human | Liver | HCC | 4.36e-05 | 3.61e-01 | 0.2503 |
25911 | DPCD | S029 | Human | Liver | HCC | 2.56e-08 | 6.11e-01 | 0.2581 |
25911 | DPCD | C04 | Human | Oral cavity | OSCC | 3.50e-31 | 1.22e+00 | 0.2633 |
25911 | DPCD | C21 | Human | Oral cavity | OSCC | 1.10e-40 | 1.18e+00 | 0.2678 |
25911 | DPCD | C30 | Human | Oral cavity | OSCC | 4.23e-38 | 1.45e+00 | 0.3055 |
25911 | DPCD | C38 | Human | Oral cavity | OSCC | 3.87e-11 | 1.13e+00 | 0.172 |
25911 | DPCD | C43 | Human | Oral cavity | OSCC | 8.08e-09 | 2.70e-01 | 0.1704 |
25911 | DPCD | C46 | Human | Oral cavity | OSCC | 4.82e-15 | 3.86e-01 | 0.1673 |
25911 | DPCD | C51 | Human | Oral cavity | OSCC | 2.86e-11 | 6.01e-01 | 0.2674 |
25911 | DPCD | C57 | Human | Oral cavity | OSCC | 1.98e-13 | 4.77e-01 | 0.1679 |
25911 | DPCD | C06 | Human | Oral cavity | OSCC | 1.53e-07 | 1.19e+00 | 0.2699 |
25911 | DPCD | C07 | Human | Oral cavity | OSCC | 3.50e-03 | 6.62e-01 | 0.2491 |
25911 | DPCD | C08 | Human | Oral cavity | OSCC | 9.32e-33 | 6.60e-01 | 0.1919 |
25911 | DPCD | C09 | Human | Oral cavity | OSCC | 3.63e-05 | 2.39e-01 | 0.1431 |
25911 | DPCD | LN22 | Human | Oral cavity | OSCC | 1.61e-08 | 9.25e-01 | 0.1733 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00991114 | Esophagus | ESCC | microtubule-based transport | 115/8552 | 190/18723 | 2.54e-05 | 2.15e-04 | 115 |
GO:00991113 | Oral cavity | OSCC | microtubule-based transport | 96/7305 | 190/18723 | 7.92e-04 | 4.27e-03 | 96 |
GO:0021591 | Oral cavity | OSCC | ventricular system development | 18/7305 | 29/18723 | 1.00e-02 | 3.49e-02 | 18 |
GO:00991112 | Prostate | BPH | microtubule-based transport | 49/3107 | 190/18723 | 8.05e-04 | 5.27e-03 | 49 |
GO:00309004 | Prostate | BPH | forebrain development | 80/3107 | 379/18723 | 1.19e-02 | 4.82e-02 | 80 |
GO:00991111 | Prostate | Tumor | microtubule-based transport | 51/3246 | 190/18723 | 6.62e-04 | 4.68e-03 | 51 |
GO:003090012 | Prostate | Tumor | forebrain development | 86/3246 | 379/18723 | 4.22e-03 | 2.11e-02 | 86 |
GO:00991115 | Thyroid | PTC | microtubule-based transport | 88/5968 | 190/18723 | 2.08e-05 | 2.08e-04 | 88 |
GO:00215373 | Thyroid | PTC | telencephalon development | 100/5968 | 248/18723 | 2.90e-03 | 1.44e-02 | 100 |
GO:00309007 | Thyroid | PTC | forebrain development | 143/5968 | 379/18723 | 8.47e-03 | 3.56e-02 | 143 |
GO:009911112 | Thyroid | ATC | microtubule-based transport | 91/6293 | 190/18723 | 2.97e-05 | 2.48e-04 | 91 |
GO:003090015 | Thyroid | ATC | forebrain development | 164/6293 | 379/18723 | 4.85e-05 | 3.87e-04 | 164 |
GO:002153712 | Thyroid | ATC | telencephalon development | 113/6293 | 248/18723 | 5.61e-05 | 4.32e-04 | 113 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DPCD | SNV | Missense_Mutation | rs780393185 | c.283C>T | p.Arg95Cys | p.R95C | Q9BVM2 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-D8-A1Y3-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicine+cyclophosphamide | SD |
DPCD | insertion | In_Frame_Ins | novel | c.262_263insCCC | p.Asn88delinsThrHis | p.N88delinsTH | Q9BVM2 | protein_coding | TCGA-AO-A0J7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
DPCD | insertion | Nonsense_Mutation | novel | c.263_264insCTTTCATCTTGTGCTAGTTACCTAG | p.Ala89PhefsTer8 | p.A89Ffs*8 | Q9BVM2 | protein_coding | TCGA-AO-A0J7-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | doxorubicin | SD | ||
DPCD | SNV | Missense_Mutation | rs757346528 | c.374G>A | p.Arg125His | p.R125H | Q9BVM2 | protein_coding | deleterious(0.02) | possibly_damaging(0.59) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
DPCD | SNV | Missense_Mutation | rs773833827 | c.484N>A | p.Ala162Thr | p.A162T | Q9BVM2 | protein_coding | deleterious(0.03) | benign(0.291) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
DPCD | SNV | Missense_Mutation | rs781093580 | c.97N>A | p.Gly33Ser | p.G33S | Q9BVM2 | protein_coding | deleterious(0.01) | probably_damaging(0.985) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DPCD | SNV | Missense_Mutation | rs780393185 | c.283C>T | p.Arg95Cys | p.R95C | Q9BVM2 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-F4-6570-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DPCD | SNV | Missense_Mutation | novel | c.75N>T | p.Lys25Asn | p.K25N | Q9BVM2 | protein_coding | deleterious(0) | possibly_damaging(0.875) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
DPCD | SNV | Missense_Mutation | c.157N>T | p.Arg53Cys | p.R53C | Q9BVM2 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
DPCD | SNV | Missense_Mutation | rs375315178 | c.284G>A | p.Arg95His | p.R95H | Q9BVM2 | protein_coding | deleterious(0) | probably_damaging(0.966) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |